We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

By LabMedica International staff writers
Posted on 31 Jan 2025

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised individuals. More...

One of the major challenges in diagnosing pneumonia is the difficulty in obtaining an appropriate sample, and frequently, no pathogen is identified. Without a clear microbiological diagnosis, broad-spectrum antibiotics are typically administered, which increases the risk of antibiotic resistance and poor patient outcomes if the wrong antibiotics are chosen. The absence of rapid and accurate diagnostic tools only worsens this situation, hindering the ability to provide tailored treatments and leading to the overuse of antibiotics. Researchers are now exploring the possibility of detecting bacterial pneumonia directly from blood samples to improve access to LRTI testing.

Rhode Island Hospital (Providence, RI, USA) has been awarded USD 1 million by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, CARB-X, Boston, MA, USA) to develop a polymerase chain reaction (PCR) method informed by RNA sequencing to detect bacterial pneumonia directly from whole blood. CARB-X is a global non-profit collaboration focused on supporting early-stage research and development of antibacterial therapies to combat the growing problem of antibiotic resistance. The aim is to detect pneumonias caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae, using whole blood samples, making it less invasive compared to traditional methods that require samples from the airways, such as bronchoscopy or deep suctioning.

This simplified approach, involving a needle-stick blood collection from the arm, has the potential to expand access to testing and streamline current LRTI testing methods, enabling testing at primary care centers around the world instead of just tertiary care settings. Unlike traditional microbiological tests, this method will not require specimen culturing, providing results in just four hours. Targeting RNA ensures that the infection is active, as RNA degrades much faster than DNA, lasting only minutes to hours when sourced from bacteria. This technique immediately stabilizes the RNA for testing, and because it targets RNA, it identifies bacteria actively producing resistance proteins, rather than simply detecting bacteria that may carry genes for resistance.

“The support from CARB-X to focus on developing a direct from blood diagnostic for lower-respiratory-tract infections expands our current NIH supported work creating a direct from blood, culture independent, diagnostic for pathogens causing sepsis targeting RNA from the bacteria using RNA sequencing data form patients,” said Sean Monaghan, MD, surgeon at Rhode Island Hospital.

“This innovative diagnostic approach holds the potential to improve access to testing for lower-respiratory-tract infections, including pneumonia, enabling clinicians to make faster, more informed decisions and reduce the use of broad-spectrum antibiotics,” added Erin Duffy, PhD, Chief of R&D and CARB-X. “By supporting Rhode Island Hospital’s work, CARB-X is learning whether alternative sample types in detecting LRTIs is promising for future product development.”

Related Links:
Rhode Island Hospital
CARB-X


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Sample Transportation System
Tempus1800 Necto
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.